Literature DB >> 25575848

Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.

Kohei Oda1, Hirofumi Uto, Seiichi Mawatari, Akio Ido.   

Abstract

Most cases of hepatocellular carcinoma (HCC) in Japan develop in the background of chronic liver disease caused by hepatitis C virus (HCV). Recently, however, HCV-associated HCC has been shown to be decreasing, while non-B and non-C HCC (NBNC-HCC), which is negative for HCV and hepatitis B virus infection, has increased. The main cause of NBNC-HCC is alcoholic liver disease, but the recent increase of NBNC-HCC is thought to be due to an increase in patients with nonalcoholic fatty liver disease (NAFLD). Approximately 10% of NAFLD cases involve nonalcoholic steatohepatitis (NASH), and NASH can progress to liver cirrhosis and its associated complications such as HCC. There are no accurate data on the percentage of NASH-related HCC among all-cause HCC in Japan, because no large-scale investigation has been performed. However, the rate is thought to be about 3% of overall HCC, which is lower than that in the United States. The incidence of HCC in patients with NASH-related cirrhosis is thought to be 2% per year, which is lower than that in HCV-related cirrhosis. Risks for NASH-related HCC include advanced hepatic fibrosis, older age, and being male. NAFLD that includes NASH is associated with metabolic syndrome, which includes obesity and diabetes, and metabolic syndrome is a risk factor for HCC. Genetic factors and dietary patterns may also be related to NASH-related HCC. Thus, regular HCC surveillance, as performed for patients with viral chronic liver disease, is required for patients with NAFLD, and diagnostic markers are required for simple, rapid and specific detection of NASH-related HCC.

Entities:  

Mesh:

Year:  2015        PMID: 25575848     DOI: 10.1007/s12328-014-0548-5

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  111 in total

1.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Kris V Kowdley; Patricia Belt; Laura A Wilson; Matthew M Yeh; Brent A Neuschwander-Tetri; Naga Chalasani; Arun J Sanyal; James E Nelson
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

2.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

3.  Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease.

Authors:  Claudia O Zein; Aynur Unalp; Ryan Colvin; Yao-Chang Liu; Arthur J McCullough
Journal:  J Hepatol       Date:  2010-09-22       Impact factor: 25.083

4.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

5.  Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.

Authors:  Yasuji Arase; Mariko Kobayashi; Fumitaka Suzuki; Yoshiyuki Suzuki; Yusuke Kawamura; Norio Akuta; Norihiro Imai; Masahiro Kobayashi; Hitomi Sezaki; Naoki Matsumoto; Satoshi Saito; Tetsuya Hosaka; Kenji Ikeda; Hiromitsu Kumada; Yuki Ohmoto; Kazuhisa Amakawa; Shiun Dong Hsieh; Kyoko Ogawa; Maho Tanabe; Hiroshi Tsuji; Tetsuro Kobayashi
Journal:  Hepatol Res       Date:  2011-12-19       Impact factor: 4.288

6.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

7.  Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis.

Authors:  Hiroko Iijima; Fuminori Moriyasu; Kaoru Tsuchiya; Shiro Suzuki; Masahiro Yoshida; Masafumi Shimizu; Shunichi Sasaki; Syuhei Nishiguchi; Shiro Maeyama
Journal:  Hepatol Res       Date:  2007-06-07       Impact factor: 4.288

Review 8.  The role of sugar-sweetened beverage consumption in adolescent obesity: a review of the literature.

Authors:  Susan Harrington
Journal:  J Sch Nurs       Date:  2008-02       Impact factor: 2.835

9.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

10.  Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study.

Authors:  Ryosuke Tateishi; Takeshi Okanoue; Naoto Fujiwara; Kiwamu Okita; Kendo Kiyosawa; Masao Omata; Hiromitsu Kumada; Norio Hayashi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2014-06-15       Impact factor: 7.527

View more
  24 in total

1.  Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis.

Authors:  Jia Cai; Shujun Zhang; Wenxiang Huang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

2.  Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/- mice by targeting the TGFβ-Smad3 pathway.

Authors:  Kelli A Lytle; Christopher M Depner; Carmen P Wong; Donald B Jump
Journal:  J Lipid Res       Date:  2015-08-27       Impact factor: 5.922

3.  Protein malnutrition during fetal programming induces fatty liver in adult male offspring rats.

Authors:  Sabrina Edith Campisano; Stella Maris Echarte; Enrique Podaza; Andrea Nancy Chisari
Journal:  J Physiol Biochem       Date:  2017-02-03       Impact factor: 4.158

4.  Discovery of JND003 as a New Selective Estrogen-Related Receptor α Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance.

Authors:  Liufeng Mao; Lijie Peng; Xiaomei Ren; Yi Chu; Tao Nie; Wanhua Lin; Xuemei Zhao; Andrew Libby; Yong Xu; Yu Chang; Chong Lei; Kerry Loomes; Na Wang; Jinsong Liu; Moshe Levi; Donghai Wu; Xiaoyan Hui; Ke Ding
Journal:  ACS Bio Med Chem Au       Date:  2022-01-31

5.  Personalized management of hepatocellular carcinoma based on molecular information: future prospects.

Authors:  Nicolas Goossens; Yujin Hoshida
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-06-01

Review 6.  The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials.

Authors:  Cian O Malley; Graham P Pidgeon
Journal:  BBA Clin       Date:  2015-11-12

Review 7.  Nonalcoholic Lipid Accumulation and Hepatocyte Malignant Transformation.

Authors:  Juanjuan Gu; Min Yao; Dengbing Yao; Li Wang; Xuli Yang; Dengfu Yao
Journal:  J Clin Transl Hepatol       Date:  2016-06-15

Review 8.  Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.

Authors:  Amedeo Lonardo; Stefano Ballestri; Giovanni Guaraldi; Fabio Nascimbeni; Dante Romagnoli; Stefano Zona; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

Review 9.  TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease.

Authors:  Li-Zhen Chen; Harry Hua-Xiang Xia; Yong-Ning Xin; Zhong-Hua Lin; Shi-Ying Xuan
Journal:  J Clin Transl Hepatol       Date:  2015-12-15

10.  A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.

Authors:  Amon Asgharpour; Sophie C Cazanave; Tommy Pacana; Mulugeta Seneshaw; Robert Vincent; Bubu A Banini; Divya Prasanna Kumar; Kalyani Daita; Hae-Ki Min; Faridoddin Mirshahi; Pierre Bedossa; Xiaochen Sun; Yujin Hoshida; Srinivas V Koduru; Daniel Contaifer; Urszula Osinska Warncke; Dayanjan S Wijesinghe; Arun J Sanyal
Journal:  J Hepatol       Date:  2016-05-31       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.